Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03086460 · ClinicalTrials.gov registry record · Phase 2
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
A Phase 2 study, sponsored by Chiesi Farmaceutici S.p.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT03086460 is a Phase 2 study that has completed, run by Chiesi Farmaceutici S.p.A.. The registered enrollment target is 67 participants.
The verdict
NCT03086460, a Phase 2 study, has completed, sponsored by Chiesi Farmaceutici S.p.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
To evaluate the dose-response of different doses of CHF 1531 pressurized metered dose inhaler (pMDI) containing formoterol fumarate, on lung function and other clinical outcomes and to identify the optimal dose(s) with regard to benefit/ risk ratio for further development in the target subject population.
Interventions
- DRUG Placebo pMDI
- DRUG CHF 1531 pMDI
- DRUG Formoterol Inhalation Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2017-09-08 |
| Est. Completion | 2018-07-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03086460
The ClinicalTrials.gov registry entry for NCT03086460 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chiesi Farmaceutici S.p.A., which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo pMDI is the first listed.
NCT03086460 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03086460 about?
NCT03086460 is a clinical study titled "A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)". To evaluate the dose-response of different doses of CHF 1531 pressurized metered dose inhaler (pMDI) containing formoterol fumarate, on lung function and other clinical outcomes and to identify the optimal dose(s) with regard to benefit/ risk ratio for further development in the target subject popul...
What is the current status of trial NCT03086460?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2017-09-08. Estimated completion is 2018-07-28.
What interventions are being tested in trial NCT03086460?
The interventions under investigation include: Placebo pMDI (DRUG), CHF 1531 pMDI (DRUG), Formoterol Inhalation Solution (DRUG).
Who is sponsoring clinical trial NCT03086460?
This trial is sponsored by Chiesi Farmaceutici S.p.A., which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.